Open AccessMucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases
Author(s) -
Erin M. Kim,
Cara Randall,
Renée Betancourt,
Staci Keene,
Amy Lilly,
Mark R. Fowler,
Evan S. Dellon,
Hans Herfarth
Publication year - 2019
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izz251
Subject(s) - vedolizumab , medicine , eosinophil , gastroenterology , ulcerative colitis , eosinophilia , inflammatory bowel disease , immunology , disease , asthma
Peripheral and mucosal eosinophilia may be associated with more aggressive disease in inflammatory bowel disease (IBD) patients. Vedolizumab blocks T lymphocytes, eosinophil adhesion, and extravasation in the gastrointestinal tract. It is not known if mucosal eosinophilia is a predictor for the therapeutic efficacy of vedolizumab.